Perez-García JM - Search Results

1

Enhancing global access to cancer medicines.

Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, Barrios CH, Wagle S, Roman J, Harbeck N, Eniu A, Kaufman PA, Tabernero J, García-Estévez L, Schmid P, Arribas J. Cortes J, et al. CA Cancer J Clin. 2020 Mar;70(2):105-124. doi: 10.3322/caac.21597. Epub 2020 Feb 18. CA Cancer J Clin. 2020. PMID: 32068901 Free article. Review.

2

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.

Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J. Vilar E, et al. Endocr Relat Cancer. 2007 Jun;14(2):221-32. doi: 10.1677/ERC-06-0074. Endocr Relat Cancer. 2007. PMID: 17639039 Review.

3

Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers.

Capdevila J, Ramos FJ, Macarulla T, Elez E, Ruiz-Echarri M, Perez-Garcia J, Tabernero J. Capdevila J, et al. Curr Opin Oncol. 2009 Jul;21(4):374-80. doi: 10.1097/CCO.0b013e32832c9464. Curr Opin Oncol. 2009. PMID: 19412097 Review.

4

Status of PI3K inhibition and biomarker development in cancer therapeutics.

Markman B, Atzori F, Pérez-García J, Tabernero J, Baselga J. Markman B, et al. Ann Oncol. 2010 Apr;21(4):683-691. doi: 10.1093/annonc/mdp347. Epub 2009 Aug 27. Ann Oncol. 2010. PMID: 19713247 Free article. Review.

5

New approaches and targets in advanced colorectal cancer.

Macarulla T, Capdevila J, Perez-Garcia J, Ramos FJ, Elez ME, Markman B, Ruiz-Echarri M, Tabernero J. Macarulla T, et al. Eur J Cancer. 2009 Sep;45 Suppl 1:79-88. doi: 10.1016/S0959-8049(09)70019-X. Eur J Cancer. 2009. PMID: 19775607 No abstract available.

6

Targeted therapies in thyroid cancer.

Capdevila J, Perez-Garcia J, Obiols G, Tabernero J. Capdevila J, et al. Target Oncol. 2009 Dec;4(4):275-85. doi: 10.1007/s11523-009-0124-y. Epub 2009 Nov 11. Target Oncol. 2009. PMID: 19904500

7

Pushing the envelope in the mTOR pathway: the second generation of inhibitors.

Vilar E, Perez-Garcia J, Tabernero J. Vilar E, et al. Mol Cancer Ther. 2011 Mar;10(3):395-403. doi: 10.1158/1535-7163.MCT-10-0905. Epub 2011 Jan 7. Mol Cancer Ther. 2011. PMID: 21216931 Free PMC article. Review.

8

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.

Muñoz-Couselo E, Pérez-García J, Cortés J. Muñoz-Couselo E, et al. Onco Targets Ther. 2011;4:185-92. doi: 10.2147/OTT.S16392. Epub 2011 Nov 14. Onco Targets Ther. 2011. PMID: 22162924 Free PMC article.

9

Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?

Pérez-García J, Cortés J. Pérez-García J, et al. Breast Cancer Res. 2012 Jan 26;14(1):104. doi: 10.1186/bcr3093. Breast Cancer Res. 2012. PMID: 22297134 Free PMC article.

10

The beautiful history of pertuzumab.

Perez-Garcia J, Muñoz-Couselo E, Ortega V, Cortes J. Perez-Garcia J, et al. Expert Rev Anticancer Ther. 2012 Jun;12(6):703-5. doi: 10.1586/era.12.46. Expert Rev Anticancer Ther. 2012. PMID: 22716485 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page